Kamada to Announce Q1 2024 Financial Results and Host Conference Call on May 8, 2024

REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company specializing in rare and serious conditions, will publish its financial results for the first quarter ending March 31, 2024, before the U.S. financial markets open on May 8, 2024. An investment community conference call is scheduled for the same day at 8:30am Eastern Time to discuss the results and address questions. Participants can join the call by dialing specified numbers based on their location, and the call will be webcast live, with an archive available for 90 days on the company's website.

Kamada Ltd. is renowned for its portfolio of plasma-derived biopharmaceutical products aimed at rare and severe diseases, areas often lacking treatment options. The company's commercial strategy is centered on leveraging its manufacturing and development prowess to drive profitable growth. Kamada’s product lineup includes six FDA-approved plasma-derived therapeutics: KEDRAB®, CYTOGAM®, VARIZIG®, WINRHO SDF®, HEPAGAM B®, and GLASSIA®. Additionally, it offers KAMRAB®, KAMRHO (D)®, and two types of anti-snake venom products derived from equine sources.

The company's products are distributed directly and through strategic partnerships across over 30 countries, including major markets like the U.S., Canada, Israel, and Russia, among others. In Israel, Kamada also distributes more than 25 pharmaceutical products from international manufacturers and has a portfolio of eleven biosimilar products anticipated to launch through 2028, pending regulatory approvals.

Kamada owns an FDA-licensed plasma collection center in Beaumont, Texas, which focuses on collecting hyper-immune plasma for products like KAMRHO (D), KAMRAB, and KEDRAB. Beyond its commercial operations, Kamada invests in the research and development of new drug candidates. The company's leading investigational product is an inhaled Alpha-1 Antitrypsin (AAT) for treating AAT deficiency, currently undergoing a Phase 3 clinical trial named InnovAATe.

The company is controlled by FIMI Opportunity Funds, Israel's leading private equity firm, which owns approximately 38% of Kamada's outstanding shares.